Loading...
OTCM
IOBCF
Market cap550mUSD
Oct 20, Last price  
19.00
Name

Ion Beam Applications SA

Chart & performance

D1W1MN
OTCM:IOBCF chart
P/E
—
P/S
—
EPS
0.42
Vol. 1Y
—
Shs. 5Y
-0.12%
Rev. 5Y
14.73%
Div Yld LY
—
Div Yld TTM
—
Revenues
620m
+24.49%
170,257,000213,849,000332,607,000332,607,000387,591,000237,694,000221,106,000212,512,000220,577,000270,357,000328,774,000236,485,000257,407,000282,552,000311,955,000312,964,000361,270,000428,717,000498,200,000620,200,000
Net income
13m
+36.56%
30,007,00013,846,0005,329,0005,329,0006,643,000-84,128,000-5,800,000-4,098,00024,294,00061,189,00024,440,000-41,658,000-4,401,0007,610,00031,921,0003,879,0006,057,000-9,110,0009,300,00012,700,000
CFO
-26m
L+157.00%
13,652,00018,034,00011,916,00011,916,00031,412,00038,268,000-30,736,0006,763,00014,969,00045,394,000-17,018,000-44,641,000-18,521,00045,893,000100,425,00085,010,00021,712,000-19,769,000-10,000,000-25,700,000
Dividend
Jun 16, 20260.2904 /sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Ion Beam Applications S.A. (IBA) is a company specializing in the design, manufacturing, and ongoing support of sophisticated medical equipment and software solutions primarily focused on treating cancer. Its operations span Belgium, the United States, and various international markets. The company's activities are broadly organized into two main divisions: 1. Proton Therapy and Other Accelerators: This segment is responsible for the engineering, construction, and maintenance of both medical and industrial particle accelerators, including complete proton therapy systems. It also delivers comprehensive, ready-to-use systems for cancer treatment leveraging proton beams. Furthermore, this division produces a variety of cyclotron machines for generating radioisotopes vital for Positron Emission Tomography (PET) and Single-Photon Emission Computed Tomography (SPECT) imaging, alongside industrial-grade accelerators used in sterilization and ionization processes. 2. Dosimetry: This division offers specialized tools and expert services aimed at enhancing the precision and minimizing errors in radiation oncology treatments, as well as in the quality assurance and calibration protocols for medical imaging systems. IBA actively engages in strategic collaborations, including a key research and development partnership with SCK CEN (the Belgian nuclear research center) focused on enabling the synthesis of Actinium-225 (225Ac), a pioneering radioisotope for cancer therapy. The company also collaborates with the University of Pennsylvania for cutting-edge research into ConformalFLASH technology. Ion Beam Applications S.A. was established in 1986 and maintains its corporate headquarters in Louvain-la-Neuve, Belgium.

Related entities

Subsidiaries (2)
IBA Dosimetry GmbH
IBA INVESTMENTS

Key people

Catherine Vandenborre
Chief Financial Officer, Head - IBA Corporate Entity · since 2025
Yves Jongen
Chief Research Officer, Managing Director, Internal Director, Representing Technofutur SA · since 2000
Henri De Romree
Deputy Chief Executive Officer, Member of the Management Board · since 2025
Olivier Legrain
Chief Executive Officer, Managing Director and Inside Director, Representative of Lamaris Group SRL · since 2012
Pierre Mottet
Chairman of the Board, Representing Saint-Denis SA · since 2013
Independent Director, Representing Much SRL · since 2024
Independent Director, Representing Nextstepefficiency · since 2020
Richard Hausmann
Independent Director, Representing Hausmann Consulting · since 2020
Hedvig Hricak
Independent Director · since 2017
Marcel Miller
Independent Director, Representing Consultance Marcel Miller SCS · since 2011
Sybille Van Den Hove
Independent Director, Representing Bridging for Sustainability SPRL · since 2018
IPO date
Jun 13, 1998
Employees
2,000
Domiciled in
BE
Incorporated in
BE
Headquarters & legal address
Chemin du Cyclotron 3
Ottignies-Louvain-la-Neuve, WBR 1348
BE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT